Oppenheimer Reiterates Outperform on PDS Biotechnology, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell reiterated an Outperform rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a $24 price target.
May 26, 2023 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell reiterated an Outperform rating on PDS Biotechnology and maintained a $24 price target.
The reiteration of the Outperform rating and maintenance of the $24 price target by Oppenheimer analyst Leland Gershell indicates a positive outlook for PDS Biotechnology. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100